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Abstract
Background—Extrapyramidal signs (EPS) are frequent in Alzheimer's disease (AD) and core 
manifestation of related diseases, i.e., dementia with Lewy bodies and Parkinson's disease; 
furthermore, Lewy bodies and AD-type pathology occur in all three conditions.
Objective—To identify clusters of EPS progression over time and their clinical and 
neuropathological correlates.
Methods—3,502 AD patients with longitudinal assessment from the National Alzheimer's 
Coordinating Center database were included; 394 provided neuropathological data. k-means 
algorithm was employed to identify clusters of EPS progression and those were compared in terms 
of cognitive profile, neuropsychiatric features and neuropathological findings.
Results—Three clusters of EPS progression were identified: no/low (n = 1,583), medium (n = 
1,259), and high (n = 660) EPS burden. Compared to those with no/low and medium EPS, those 
with high EPS had greater cognitive and neuropsychiatric impairment, specifically hallucinations. 
Despite similar AD-pathology across the three clusters, the high EPS cluster had a significantly 
number of subjects diagnosed with dementia with Lewy bodies.
Conclusions—Cluster analysis of EPS progression over time identified different subgroups of 
AD patients with distinct clinical and neuropathological features.
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Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by 
cognitive impairment, predominantly in the memory domain, and is the leading cause of 
dementia in the elderly [1]. Most studies assess AD as a single phenotypic outcome 
(presence versus absence of the disease), neglecting the heterogeneity of the disease. In fact, 
motor and psychiatric manifestations, in particular extrapyramidal signs (EPS) and 
hallucinations, are frequently observed. In patients with incident AD, the frequency of EPS 
is approximately 12% in the early stages of the disease and increase at an annual rate of 
about 1.3% [2]. In addition, patients with EPS tend to have a faster rate of cognitive decline 
compared to those without EPS [3]. Hallucinations in AD are also frequent, can be visual or 
auditory [4], and are associated with faster cognitive and functional decline [5].
These clinical signs and symptoms are present in AD as well as in dementia with Lewy 
bodies (DLB) [6] and in Parkinson's disease (PD) [7], with these three entities also sharing 
neuropathological features. The brains of patients clinically diagnosed with AD often have 
Lewy bodies in addition to amyloid plaques and neurofibrillary tangles. For DLB, the 2005 
Criteria Consortium [6] revised the pathologic diagnosis, highlighting the degree of overlap 
between AD and Lewy body pathology, with a focus on the anatomic distribution of the 
latters. Therefore, these most recent definitions have moved toward defining DLB as a 
clinicopathologic entity. Ultimately, brains of patients diagnosed with PD often show, in 
addition to Lewy bodies, neurofibrillary tangles and amyloid plaques [8]. Thus, while AD, 
DLB, and PD are currently defined as individual disease entities, it remains possible that 
they actually reflect a continuum of a single spectrum disorder [9].
Clinical and neuropathological substrates of EPS in patients with AD have generated 
conflictive results: in order to clarify this aspect of the disease, we capitalized on the data 
extracted from the National Alzheimer's Coordinating Center (NACC) cohort aiming to 
group subjects into clusters with respect to the presence and progression of EPS over time 
and to investigate clinical and neuropathological correlates of these clusters. Many statistical 
methods have been developed to address this issue: k-means [10] is one of the most popular 
clustering algorithms applied to longitudinal data.
Methods
Study sample
The study population consisted of patients enrolled in the National Alzheimer's 
Coordinating Center Uniform Data Set (NACC UDS) [11]. Patients were seen 
approximately annually at one of the 34 Alzheimer's Disease Centers (ADCs). The Uniform 
Data Set (UDS) includes standardized data collection forms that capture information on 
demographic and clinical subject characteristics. Written informed consent was obtained 
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from all participants and their study partners. Research using the NACC database was 
approved by the Institutional Review Board at the University of Washington. More detailed 
information on the NACC database can be found online (http://www.alz.washington.edu).
For inclusion in this study, patients: (1) were 60–90 years old at the initial UDS visit; (2) 
had a primary diagnosis of probable or possible AD dementia [12] at the initial UDS visit; 
and (3) had a least two UDS visits with non-missing Unified Parkinson's Disease Rating 
Scale (UPDRS) – part III score at the time of data abstraction. Individuals with diagnosis 
other than AD were then excluded. Visits with reported use of medications for PD (e.g., 
levodopa or dopaminergic agents) or antipsychotic medications were excluded from further 
analyses. Data from visits six or more years after the initial visit were excluded.
Main outcome
Extrapyramidal signs were measured by trained and certified clinicians for 
neurodegenerative disorders using the UPDRS-part III [13] approximately annually for up to 
five years. For each visit, UPDRS items were summed to create a total score ranging from 0 
(absence of extrapyramidal signs) to a maximum of 108 (maximum impairment).
Clinical assessment
Potential correlates of EPS progression included neuropsychiatric symptoms and cognitive 
function. The Neuropsychiatric Inventory (NPI-Q) [14] collects information regarding 
depression, apathy, hallucinations, delusions, and nighttime behaviors. Reported cognitive 
fluctuation was also considered as additional correlate. Cognitive function was measured 
using the Mini-Mental Status Examination (MMSE) [15] and the Clinical Dementia Rating 
Sum of Boxes score (CDR-SB) [16]. The CDR rates subjects' cognitive and functional 
abilities in six domains: memory, orientation, judgment and problem solving, community 
affairs, home and hobbies, and personal care. The clinician, incorporating input from the 
subject's co-participant, evaluated impairment in each domain as none (0), questionable or 
very mild (0.5), mild (1), moderate (2), or severe (3). The scores for each domain were 
summed to create a Sum of Box score ranging from 0 to 18, with higher scores indicating 
more severe impairment.
Neuropathological assessment
Neuropathology data were available for a subset of these participants that had the last 
clinical evaluation within two years of death (n = 394, 11%). For this group of patients, we 
compared clusters across the following diagnoses: 1) primary neuropathologic diagnoses, 
including AD [17] and DLB (adapting the 2005 Consensus criteria [6], which considered the 
overlap of AD and Lewy body type pathology in order to profile the likelihood that the 
clinical syndrome is due to DLB pathology) and 2) presence of large artery infarct or 
hemorrhagic events and small artery infarcts and/or hemorrhages (i.e., lacunes). For most 
analyses, neuropathological categories were collapsed; for example, three categories were 
created for Braak stage [18]: lesser stages (0 through II), intermediate stages (III and IV) and 
higher stages (V and VI, representing extensive neocortical neurofibrillary tangles). Features 
assessed by neuropathologists are described in the NACC Neuropathology Guidebook 
(https://www.alz.washington.edu/NONMEMBER/NP/npguide9.pdf).
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Covariates
Analyses were adjusted for I) gender, II) age at most recent UDS visit, III) age at cognitive 
symptom onset, IV) number of follow-ups, and V) years of education. Age at onset of 
cognitive decline is reported by the clinician with input from medical records, direct 
observation, and subject/informant report.
Statistical analysis
Progression of extrapyramidal signs was determined by drawing sub-clusters of escalating 
severity employing the KmL package (http://cran.r-project.org/web/packages/kml/), an 
implementation of k-means designed to cluster longitudinal data. Briefly, this is a hill-
climbing algorithm belonging to the EM class (Expectation-Maximization). First, the 
algorithm picks n items and labels them as initial centroids; then, it assigns each point to the 
nearest centroid and finally updates the centroid of each cluster on the basis of the elements 
that are grouped together. The previous steps are then repeated until every point is stably 
assigned to one of n clusters. The selection method does not require normality or other 
parametric assumptions, nor any assumption regarding the trajectory's shape. In addition, it 
is independent of time scaling and able to handle missing data. The optimal number of 
clusters is unknown a priori: one possible solution is to run multiple analyses with different 
numbers of clusters and ultimately choose the best model. Alternatively, use of the Calinski 
& Harabatz criterion [19] allows selection of the optimal number of clusters. This approach 
combines the within-cluster and between-cluster covariance matrix (i.e., indicators of 
cluster's compactness and distance). Optimal clusters distinction has large between-cluster 
variance and a small within-cluster variance, thus the higher Calinski-Harabasz index value, 
the better the solution of clusters found.
Study demographics and cluster assignment were explored through χ2 statistics, Kruskal-
Wallis tests, or analysis of variance depending on the nature of the variable. The association 
between clinical and demographic characteristics with EPS progression cluster assignment 
was evaluated using multinomial logistic regression, reported as odd ratios (OR). 
Demographic and cognitive assessment data came from the most recent UDS visit; the 
subjects were labeled as free of neuropsychiatric symptoms if never reported in any of the 
available follow-ups. In the reduced model, each characteristic was the predictor and the 
EPS cluster indicator was the outcome measure, adjusting for gender, age at onset, age at 
last evaluation, number of available follow-ups, and years of education. As supplementary 
analyses, we employed a generalized linear mixed model that included the different ADC 
centers as a random effect to adjust for possible center variability.
Differences in the proportion of subjects for each primary neuropathological diagnoses, 
Braak staging, and Lewy body pathology (and their overlap) were tested using a χ2 test or 
Jonckheere Trend Test. Fisher's exact tests were computed when sparse or unbalance tables 
did not meet assumptions for asymptotic methods.
Post-hoc testing was carried out in order to address comparisons between the three clusters, 
adjusting for false discovery rate (FDR) correction [19]. Analyses were performed using R 
version 3.0.2 and SAS version 9.3.
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Results
Of the 9,655 subjects with possible/probable AD in the NACC-UDS database, 3,502 met all 
study inclusion criteria, and of these, 394 (11%) provided neuropathology data. A flow chart 
describing the exclusion criteria and resulting sample sizes at each step is reported in Fig. 1
KmL analyses
The K-means algorithm was applied to UPDRS longitudinal data from the NACC data set, 
restricted to patients who met all inclusion criteria described above. Potential cluster 
numbers ranging from two to six were tested in order to choose the model that best 
described the UPDRS trajectories in the study population. On the basis of the Calinski and 
Harabatz criterion (highest score = best partition), the “three clusters” was selected as the 
best solution (Fig. 2). The three clusters solution resulted in 1,583 subjects in cluster A 
(no/low EPS); 1,259 in cluster B (medium EPS); and 660 in cluster C (high EPS): a 
spaghetti plot of observed trajectories and the three resulting cluster trajectories are 
illustrated in Fig. 3. Overall, the UPDRS total score for the entire sample progresses from a 
median of 2 to a median of 4, after a maximum of five years of follow-up. Cluster analysis, 
on the contrary, disentangled the heterogeneity of the whole sample by identifying three 
distinct clusters: cluster A (no/low EPS) ranging from 0 points at baseline to 0 points at the 
end of follow-up, cluster B (medium EPS load) ranging from 4 to 7, and cluster C (high EPS 
load) ranging from 12 to 19 points. A Kruskal-Wallis test showed that the three clusters 
were significantly different from each other in terms of UPDRS score at each time interval 
(p < 0.001).
Study demographics
Study demographics and clinical characteristics are illustrated in Table 1. Subjects in the 
cluster with medium EPS load were less likely to be female compared to the other two 
clusters. Clusters with medium and high EPS showed an older age of onset and consequently 
an older age at last evaluation (p < 0.001 for both variables); ultimately, time from onset to 
study enrollment was not significantly different across the three clusters.
Clinical assessment
Compared to those with no/low EPS, those with medium and high EPS (labeled as cluster 
“A”, “B”, and “C”, respectively in Table 2) more often had apathy and nighttime aberrant 
behaviors. No significant differences were found between the three clusters with regards to 
delusions or depression. When those with high EPS were compared to those with medium 
EPS, only hallucination and cognitive fluctuation proved to be statistically different (p ≤ 
0.001), whereas no significant differences were found between individuals with no/low and 
medium EPS.
Global cognitive measures were all significantly different across the three clusters: MMSE 
and CDR at the last visit indicated significantly more severe impairment for subjects in the 
cluster with high EPS compared to those in clusters with medium and no/low EPS (Table 2). 
Results obtained through the multinomial logistic regression model were further confirmed 
through the generalized linear mixed model adjusting for ADC centers as a random effect.
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Neuropathological assessment
Patients with available neuropathological data were included if they had their last clinical 
evaluation within two years of death (n = 394; 124 were in the no/low EPS cluster, 155 in 
the medium EPS cluster, and 115 in the high EPS cluster; Table 3). Overall, AD was 
reported as the primary neuropathological diagnosis for 295 individuals (75%). Other 
primary diagnoses were as follow: 16 vascular dementia (4%), 19 frontotemporal dementia 
(5%), and 9 hippocampal sclerosis (2%). Five individuals, despite being diagnosed with 
dementia, had normal brains (1%). Twenty-one individuals were assigned to the DLB group 
(5%) as having a “high likelihood” of diagnosis according to the 2005 Consensus criteria. 
Finally, 29 subjects had very rare diagnoses (one individual per category, <1%) or multiple 
coexisting pathologies such as no diagnosis could be assigned as a predominant cause of the 
dementia. The frequency of AD identified as the primary underlying cause of the dementia 
was higher in the cluster with none/low EPS progression, although results were not 
significant after multiple testing correction (none/low EPS=81%, medium EPS=73%, and 
high EPS=70%; Table 3). However, the likelihood that the clinical syndrome was due to 
DLB pathology was higher for those subjects in the high EPS cluster (11%) as compared to 
clusters with no/low (2%) or medium EPS (3%). None of the other neuropathological 
diagnoses significantly differed across clusters. All findings were confirmed employing the 
generalized linear mixed model with ADC center as a random effect (data not shown). We 
also compared clusters by AD pathology: restricting the analysis to those with AD as a 
primary diagnosis, Braak staging did not differ significantly across clusters (p = 0.10). 
Differences in the vascular pathology were also tested: no cluster showed statistically 
significant higher frequency of such events (albeit the cluster with moderate EPS show 
higher occurrence of lacunes at a trend level).
Discussion
Using data from the National Alzheimer's Coordinating Center, we analyzed a large cohort 
of patients with clinically diagnosed AD, focusing on extrapyramidal signs, a frequent but 
often underestimated manifestation of the disease. The study cohort included up to five 
yearly follow-up visits with diagnostic, neurological, and neuropsychiatric assessments; 
compared to cross-sectional designs, longitudinal studies are known to be more robust in 
model selection and show higher statistical power [20].
The clustering algorithm identified specific subgroups of AD patients showing no/low, 
medium, and high EPS burden. By grouping together profiles of EPS progression in a large 
AD cohort, we investigated the heterogeneity of the rate of EPS progression avoiding 
reductive and arbitrary descriptions in terms of presence/absence of extrapyramidal signs.
Several findings were of particular interest. First, the cluster with no/low EPS grouped 
together individuals who had a median score of 0 with interquartile range from 0 to 2 points 
through the follow-up: this is not surprising since a score of 1 on many UPDRS sub-domains 
(i.e., mild impairment) is only mildly informative and can be considered normal. In addition, 
inter-rater agreement is poor for low scores [21]. Second, EPS increase corresponded to 
more severe cognitive impairment (i.e., high EPS cluster > medium EPS cluster > no/low 
EPS cluster), in line with the notion that motor impairment in AD is associated with faster 
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cognitive decline. Third, compared to cluster with no/low EPS, clusters with medium and 
high EPS load exhibited more severe neuropsychiatric impairment (nighttime behaviors and 
apathy). On the contrary, hallucination and cognitive fluctuation proved to be significantly 
more frequent in the high EPS cluster whereas did not differ between the no/low and 
medium EPS cluster: in other words, hallucinations tend to be co-expressed with high EPS 
burden.
Neuropathology data confirmed distinct characteristics between the clusters: the high EPS 
cluster stood out, showing the higher percentage of individuals diagnosed with DLB (11%) 
compared to the no/low (2%) and medium EPS (3%) clusters. This is also in line with the 
reported higher frequency of hallucinations in the high EPS cluster and with previous reports 
showing a strong association between reported hallucinations and Lewy body pathology at 
autopsy [22]. Thus, the high EPS cluster might be referred to what is commonly defined as 
the “Lewy body variant of AD” [23].
On the contrary, similar neuropathological findings in the clusters with no/low and medium 
EPS allow us to propose that EPS in clinically diagnosed AD might underpin a more 
heterogeneous pathogenic process: this might explain why previous observations showed 
inconsistent findings, such as linking EPS to Lewy bodies or, on the contrary, failing to 
demonstrate such association [24] or, ultimately, reporting association between EPS and 
other neuropathological features, e.g., tangle pathology [25, 26].
In order to exclude alternative causes of EPS, presence of large artery ischemic or 
hemorrhagic events or small arteries measures were compared across clusters; however, no 
statistically significant differences were found between the three clusters.
This approach also has caveats. First, in clustering analyses, there is often no “correct 
answer” for the right number of clusters [27]; this limitation should then be taken into 
account and further validations with alternative methods considered. Nevertheless, we 
validated the three clusters by showing their differences in terms of clinical and 
neuropathological features. Second, although excluding visits with reported antipsychotic 
and antiparkinsonian agents reduced bias for drug-induced events, it could not be ruled out 
that EPS or hallucinations were independently present. Third, subjects in the cluster with 
no/low EPS could be in an earlier stage of the disease and would have later developed EPS 
along with neuropsychiatric manifestations; nevertheless, albeit showing lower age at 
evaluation (cluster A < cluster B < cluster C), age of onset is accordingly lower for cluster 
with no/low EPS. Furthermore, time from disease onset to study enrollment was similar, 
making it unlikely that the three clusters are earlier or later stages of the same diseases 
process while it suggests a faster disease progression for subjects with EPS compared to 
those without EPS. This concern might also be true for the neuropathology assessment, 
although findings of similar Braak staging for those with an AD diagnosis again suggests 
that the three clusters reflect different diseases expressions rather than stages of disease. 
Four, we assessed EPS as a total score without dissecting the structure of UPDRS (e.g., 
rigidity, tremor etc.): the latter has never been investigated in AD to our knowledge (data are 
only available for PD), thus profiling specific sub-domains of EPS might be controversial. 
Finally, the NACC database collects data from AD research centers and is not population-
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based; further, subjects who are followed and/or who have donated brains for autopsy may 
not be generalizable to any specific population and represent only a small portion of the 
initial clinical sample. To account for inter-center variability, a generalized linear mixed 
model was also employed, with the AD centers as a random effect: nevertheless, all reported 
results were confirmed.
Our data provide further evidence that the neuropathological underpinning of AD differs for 
distinct phenotype patterns. These results also demonstrate that k-means clustering analysis 
is a useful method for characterizing the heterogeneous nature of AD and for examining the 
relationships between clinical and neuropathological findings in AD sub-phenotypes. This 
approach may be particularly helpful in generating hypotheses that could investigate the 
variability of symptoms and support the development of novel treatment approaches for AD.
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Fig 1. 
Flow chart showing selection criteria and sample numerosity at each step. AD, Alzheimer's 
disease; AAO, age at onset; UPDRS, Unified Parkinson's Disease Rating Scale.
Tosto et al. Page 11
J Alzheimers Dis. Author manuscript; available in PMC 2016 November 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig 2. 
Potential cluster solutions and Calinski-Harabatz (CH) index. X-axis shows all potential 
cluster solutions tested; Y-axis shows standardized CH index (1 = best solution; 0 = worst 
solution).
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Fig 3. 
KmL plot. Each line defines a single patient's UPDRS score progression during follow-up. 
The “A” line represents the cluster with no/low EPS load, the “B” line the cluster with 
medium EPS load, and the “C” line the cluster with high EPS load. X-axis, years of follow-
up; Y-axis, UPDRS total score.
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Table 1
Demographics and clinical characteristics of the dataset, overall and stratified by 
extrapyramidal signs (EPS) cluster
Overall population (n = 3,502)
Age at most recent visit mean (SD) 79.8 (6.6)
Female (%) 54.6
Age at onset mean (SD) 72.9 (6.6)
Education (years) mean (SD) 14.4 (3.7)
UPDRS median (IQR)
 Baseline 2 (6)
 Last visit 4 (11)
Subjects known to be deceased (%) 880 (25.1)
Cluster A (no/low EPS) B (medium EPS) C (high EPS)
Number of individuals 1,583 1,259 660
Female (%) 57.9 50.8 54.2
Education (years) mean (SD) 14.5 (3) 14.4 (3) 14.1 (4)
Age of onset of cognitive decline mean (SD) 71.5 (6) 73.6 (6) 75.1 (6)
Age at baseline (SD) 76.0 (6) 78.2 (6) 80.0 (6)
Age at most recent visit mean (SD) 78.3 (6) 80.5 (6) 82.2 (6)
Depression (%) 54.2 54.8 55.6
Hallucinations (%) 13.2 14.1 20.3
Apathy (%) 63.8 69.3 70.7
Delusions (%) 29.3 31.5 32.8
Erratic nighttime behaviors (%) 46.2 53.2 55.3
Fluctuating cognition (%) 11.6 11.8 23.2
Mean MMSE at baseline (SD)† 22.9 (5) 22.4 (5) 20.9 (6)
Mean CDR-SB at baseline (SD)a 4.2 (3) 4.9 (3) 5.9 (4)
Mean MMSE at last visit (SD)† 18.1 (6.4) 17.0 (6.3) 15.9 (7.0)
Mean CDR-SB at last visit (SD)a 7.9 (4.0) 8.9 (4.1) 10.1 (4.4)
UPDRS median (IQR)
 Baseline 0 (1) 4 (7) 12 (10)
 Last visit 0 (2) 7 (6) 19 (12)
†8 subjects in cluster A, 14 subjects in cluster B and 15 subjects in cluster C were missing MMSE score.
J Alzheimers Dis. Author manuscript; available in PMC 2016 November 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Tosto et al. Page 15
Ta
bl
e 
2
R
es
ul
ts
 o
f m
ul
tip
le
 m
ul
tin
om
ia
l l
og
ist
ic
 r
eg
re
ss
io
n 
co
m
pa
ri
ng
 o
dd
s o
f U
PD
R
S 
tr
aje
cto
ry
 ty
pe
 st
ra
tif
ied
 by
 su
bje
ct 
fea
tur
es 
in 
AD
C
lu
st
er
 B
 v
er
su
s A
 (m
ed
ium
 ve
rsu
s n
o/l
ow
 E
PS
)
C
lu
st
er
 C
 v
er
su
s A
 (h
igh
 ve
rsu
s n
o/l
ow
 E
PS
)
C
lu
st
er
 C
 v
er
su
s B
 (h
igh
 ve
rsu
s m
ed
ium
 E
PS
)
C
ha
ra
ct
er
ist
ic
O
R
 (9
5%
 C
I)
p
O
R
 (9
5%
 C
I)
p
O
R
 (9
5%
 C
I)
p
N
eu
ro
ps
yc
hi
at
ric
 a
ss
es
sm
en
t
D
ep
re
ss
io
n
1.
14
 (0
.98
–1
.33
)
0.
15
1.
30
 (1
.07
–1
.58
)
0.
02
1.
14
 (0
.94
–1
.39
)
0.
18
D
el
us
io
ns
1.
10
 (0
.93
–1
.30
)
0.
44
1.
12
 (0
.91
–1
.37
)
0.
44
1.
02
 (0
.83
–1
.25
)
0.
87
A
pa
th
y
1.
31
 (1
.11
–1
.54
)
0.
00
1
1.
55
 (1
.26
–1
.91
)
<
0.
00
1
1.
19
 (0
.96
–1
.47
)
0.
11
N
ig
ht
tim
e 
be
ha
vi
or
s
1.
29
 (1
.11
–1
.50
)
0.
00
1
1.
45
 (1
.20
–1
.76
)
<
0.
00
1
1.
13
 (0
.93
–1
.37
)
0.
22
H
al
lu
ci
na
tio
ns
1.
10
 (0
.88
–1
.37
)
0.
39
1.
68
 (1
.31
–2
.17
)
<
0.
00
1
1.
53
 (1
.18
–1
.97
)
0.
00
1
Co
gn
iti
ve
 fl
uc
tu
at
io
n
1.
10
 (0
.85
–1
.41
)
0.
47
2.
73
 (2
.06
–3
.61
)
<
0.
00
1
2.
49
 (1
.87
–3
.39
)
<
0.
00
1
Co
gn
iti
ve
 a
ss
es
sm
en
t
M
M
SE
 sc
or
e
0.
96
 (0
.95
–0
.98
)
<
0.
00
1
0.
93
 (0
.91
–0
.94
)
<
0.
00
1
0.
96
 (0
.94
–0
.97
)
<
0.
00
1
CD
R-
SB
 sc
or
e
1.
10
 (1
.06
–1
.10
)
<
0.
00
1
1.
16
 (1
.14
–1
.20
)
<
0.
00
1
1.
08
 (1
.05
–1
.10
)
<
0.
00
1
O
R,
 o
dd
s r
at
io
; C
I, 
co
nf
id
en
ce
 in
te
rv
al
; p
, p
-
v
al
ue
. p
-
v
al
ue
s a
re
 p
re
se
nt
ed
 in
 b
ol
d 
if 
sig
ni
fic
an
t a
fte
r m
ul
tip
le
 te
sti
ng
 c
or
re
ct
io
n.
 A
na
ly
se
s a
dju
ste
d f
or 
ge
nd
er,
 ag
e a
t la
st 
vis
it, 
ag
e a
t o
nse
t, n
um
be
r o
f 
fo
llo
w
-u
ps
, a
nd
 y
ea
rs
 o
f e
du
ca
tio
n.
J Alzheimers Dis. Author manuscript; available in PMC 2016 November 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Tosto et al. Page 16
Table 3
Neuropathological findings stratified by cluster in those undergoing autopsy (n = 394)
Cluster A (no/low EPS) Cluster B (medium EPS) Cluster C (high EPS) p*
Number of individuals 124 155 115
Age at death (SD) 81.7 (7) 84.5 (6) 84.5 (5) <0.001
Primary diagnosis 0.003
 Diagnosis of Alzheimer's disease (%) 101 (81) 113 (73) 81 (70) ns
 Diagnosis of dementia with Lewy bodies (%) 3 (2) 5 (3) 13 (11) <0.05
 Diagnosis of frontotemporal dementia (%) 3 (2) 10 (6) 6 (5) ns
 Diagnosis of vascular dementia (%) 1 (1) 8 (5) 7 (6) ns
 Diagnosis of hippocampus sclerosis (%) 2 (2) 7 (4) 0 (0) ns
 Normal Brain (%) 3 (2) 0 (0) 2 (2) ns
 Other (%) 11 (9) 12 (8) 6 (5) ns
Braak staging† ns
0–I–II (%) 0 (0) 2 (2) 1 (1)
III–IV (%) 12 (12) 16 (14) 16 (20)
V–VI (%) 89 (88) 94 (84) 64 (79)
Missing 0 1 0
Vascular assessment
large artery cerebral infarcts 9 (7) 12 (8) 12 (10) ns
Hemorrhages 6 (5) 10 (6) 3 (3) ns
lacunes (small artery infarcts and/or hemorrhages) 16 (13) 35 (22) 16 (14) 0.06
*χ2 test for a difference in proportions among the 3 clusters for primary neuropathological diagnosis; Trend test for Braak stages.
†Analyses restricted to those with AD as a primary neuropathological diagnosis. Percentages have been rounded to nearest whole percent; ns = non 
significant.
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